Pharvaris

About Pharvaris

Pharvaris is a late-stage biopharma company focused on developing novel oral therapies for hereditary angioedema (HAE) and other bradykinin-mediated diseases. Their mission is to provide freedom from angioedema symptoms and attacks, offering injectable-like efficacy and placebo-like tolerability in oral treatments, aiming to improve the quality of life and standard of care for patients.

Products & Services

Deucrictibant (Prophylactic Treatment):A pivotal Phase 3 study (HAE CHAPTER-3) for the prophylactic treatment of HAE attacks.

Oral Bradykinin B2 Receptor Antagonists:Novel oral therapies targeting bradykinin-mediated diseases like HAE and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

Specialties

Hereditary Angioedema (HAE) Bradykinin-Mediated Diseases Oral Therapy Development Clinical Trials for Angioedema oral bradykinin B2 receptor antagonists bradykinin-mediated diseases hereditary angioedema (HAE)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Offering T: - FT: Equity Offering	A: 132300000 MR: - FA: 132.3 million FAN: 132300000	D: 2026-05-11 FD: 2026-05-11	4 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 115000000 MR: - FA: approximately $115 million FAN: 115000000	D: 2026-05-08 FD: 2026-05-08	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 201200000 MR: - FA: approximately $201.2 million FAN: 201200000	D: 2025-07-24 FD: 2025-07-24	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150,000,000 FAN: 150000000	D: 2025-07-22 FD: 2025-07-22	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: approximately $175 million FAN: 175000000	D: 2025-07-22 FD: 2025-07-22	5 investors
6	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 300000000 MR: - FA: approximately $300 million FAN: 300000000	D: 2023-12-06 FD: 2023-12-06	3 investors
7	RT: Private Placement T: - FT: Private Placement	A: 70000000 MR: - FA: $70 million FAN: 70000000	D: 2023-06-20 FD: 2023-06-20	5 investors

Equity Offering Latest

2026-05-11

$132.3M

4 investors (Pro only)

Underwritten Public Offering 2026-05-08

$115.0M

Public Offering 2025-07-24

$201.2M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Berndt Modig

Chief Executive Officer, Director (CH)

S

Stefan Abele

Chief Technical Operations Officer (CH)

A

Annick Deschoolmeester

Chief Human Resources Officer (CH)

A

Anne Lesage

Chief Early Development Officer (BE)

P

Peng Lu

Chief Medical Officer (U.S.)

D

David Nassif

Chief Financial Officer & Chief Legal Officer (U.S.)

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Pharvaris Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised